Click to print
Search
Search for Bupa recognised healthcare professionals and services. Consultant search
Keywords: Town/Postcode: Consultant name:

LloydsPharmacy Clinical Homecare

Nursing - general 80008694

  • is not fee assuredNot Fee assured
Overview
Not Fee assured

Offers

  • Face-to-face consultations
  • Home chemotherapy

About me

Lloyds Pharmacy Clinical Homecare (LPCH) provides care to more than 85,000 patients in the comfort of their home or in the community every year. All of our services are registered with the Care Quality Commission and are delivered by our highly qualified nurses who are all registered with the Nursing and Midwifery Council.

As a Bupa insured patient having your oncology care provided by LPCH, you’ll receive personalised care from our oncology nurses either in your home or at one of our private out-patient healthcare centres (see the map below for more details). Your care will be supervised and coordinated at all times by the consultant treating you.

Our services have many benefits including:
• 1:1 specialised oncology nursing
• A bespoke treatment plan that suits your needs and availability
• Care delivered in the most convenient setting outside of a hospital
• A clean and safe environment
• Care coordinated with the consultant treating you
• Free parking and a range of amenities, including refreshments and Wi-Fi, at our private out-patient clinics

How it works:
Any Bupa recognised consultant can refer you to have your oncology care provided by LPCH. However the consultant treating you will need to agree that it’s medically appropriate for you to have your care provided by LPCH.
Once the consultant treating you refers you for oncology care provided by LPCH, you’ll be given a dedicated patient care manager. They will supervise your care plan and be there to give you a warm welcome, explain how your care will be delivered and answer any questions you may have.
Your care plan will be divided into cycles, and the number you need will be determined by the consultant treating you. Every cycle will include:
• Having blood taken, at the request of your consultant, normally 48 hours before your next cycle. This can take place at the healthcare centre or at your home depending on where you receive your oncology care.
• A remote consultation with one of our nurses once your blood results have been received.
• Treatment either at home or at our private out-patient healthcare centres

Areas of interest

● Cancer
● Homecare
● Oncology
● Immunotherapy
● Chemotherapy
● Systemic Anti-Cancer Therapy (SACT) Pre-Assessments
● Mobile Units
● Sub-cutaneous pharmacy injection clinics
● Health Centres
● Community
● SACT Intervention
● Lloyds Pharmacy Clinical Homecare (LPCH)
● Lloyds

Medical secretaries

Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • 0025B

    BH5 PRE COMPOUNDING TEST - (>50)

  • AA999

    Oral Chemotherapy Drugs Delivery Costs - (>50)

  • AA997

    Infusion Chemotherapy Drugs Delivery Costs - (>50)

  • AA998

    Injection Chemotherapy Drugs Delivery Costs - (>50)

  • AD804

    abiraterone (Zytiga) - 500mg tablet - (>50)

  • AD798

    capecitabine (non-proprietary) - 500mg tablets - (>50)

  • AD988

    Pegfilgrastim (Pelmeg) 6mg/0.6ml pre-filled syringe - (>50)

  • AD966

    Erleada (apalutamide) 112 x 60mg tablets - (>50)

  • AD855

    bevacizumab (Aybintio) - 100mg/4ml solution for infusion vials - (5-50)

  • AA862

    Cancer related line insertion (i.e. PICC/Central) - Nurse Led - (5-50)

  • AD930

    Palbociclib (Ibrance) 75mg capsules - (5-50)

  • AD871

    Zoledronic acid (Non-proprietary) 4mg/100ml solution for infusion vials - (5-50)

  • AD950

    Verzenios (Abemaciclib) 150mg x 28 tablets - (5-50)

  • H120F

    Paclitaxel - (5-50)

  • AD846

    osimertinib (Tagrisso) 80mg tablets - (5-50)

  • AE058

    Enfortumab vedotin (Padcev) 30mg - (5-50)

  • AD949

    Verzenios (Abemaciclib) 100mg x 28 tablets - (5-50)

  • AD824

    fulvestrant (non-proprietary) 250mg/5ml solution for injection pre-filled syringes - (5-50)

  • AD935

    ribociclib (Kisqali) 200mg tablets x 63 - (5-50)

  • AD820

    pertuzumab/trastuzumab (Phesgo) 600mg/600mg/10ml solution for injection vials - (5-50)

  • AD861

    cyclizine (Non-proprietary) 50mg tablets - (5-50)

  • 0024B

    BH4 PRE COMPOUNDING TEST - (5-50)

  • AD818

    acalabrutinib (Calquence) 100mg capsules - (5-50)

  • AD948

    Verzenios (Abemaciclib) 50mg x 28 tablets - (5-50)

  • AD990

    Ibrutinib (Imbruvica) 280mg tablets - (5-50)

  • AD863

    everolimus (Non-proprietary) 5mg tablets - (5-50)

  • AD943

    Olaparib (Lynparza) 150 MG - (5-50)

  • AD845

    lenalidomide (Revlimid) - 2.5mg capsules - (5-50)

  • AE090

    Relugolix (Orgovyx) 120mg tab - (5-50)

  • AD797

    capecitabine (non-proprietary) - 150mg tablets - (5-50)

  • AD827

    darolutamide (Nubeqa) 300mg tablets - (5-50)

  • AD812

    lorlatinib (Lorviqua) - 25mg tablets - (5-50)

  • AD992

    Lorlatinib (Lorviqua) 30 x 100mg tablets - (5-50)

  • AD957

    Lenvatinib (Kisplyx) 10mg capsule - (5-50)

  • AD923

    atezolizumab (Tecentriq) 1200 mg concentrate for solution for infusion - (5-50)

  • AD853

    trastuzumab deruxtecan (Enhertu) 100 mg powder for concentrate for solution for infusion - (1-5)

  • 0021B

    BH1 PRE COMPOUNDING TEST - (1-5)

  • AD933

    alectinib (Alecensa) 600mg (4 tablets) - (1-5)

  • AD805

    talazoparib (Talzenna) - 0.25mg capsules - (1-5)

  • AA870

    Line flush care - Nurse led - (1-5)

  • AD864

    pemetrexed (Non-proprietary) 1000mg/40ml concentrate for solution for infusion vials - (1-5)

Report this page Edit details

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.